Mifepristone
FDA-approved product (tablet, oral), marketed as Korlym, Mifeprex, Mifepristone.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cushing syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Progesterone receptor modulators
- FDA pharmacologic class
- Progestin Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Mifepristone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Mifepristone and Mid-Trimester Termination of Pregnancy
NCT00382538 · start 2005-03
Registered record
- Registry ID
- NCT00382538
- Conditions
- Abortion, Induced; Abortion, Second Trimester
- Interventions
- Addition of mifepristone 200 mg 24 hours before induction
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-03
- Completion
- 2006-11
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, Induced; Abortion, Second TrimesterInterventionAddition of mifepristone 200 mg 24 hours before inductionPhaseNot applicableRegistry statusCompletedThe Effect of Mifepristone on Uterine Fibroids and Breast Tissue
NCT00579475 · start 2004-11
Registered record
- Registry ID
- NCT00579475
- Conditions
- Uterine Fibroids
- Interventions
- Mifegyne; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2004-11
- Completion
- 2007-06
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUterine FibroidsInterventionMifegyne; placeboPhasePhase 1Registry statusCompletedBrain Receptor Function in Post-Traumatic Stress Disorder
NCT00046553 · start 2002-09
Registered record
- Registry ID
- NCT00046553
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- RU-486 (Mifepristone)
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2002-09
- Completion
- 2004-10
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-Traumatic Stress DisorderInterventionRU-486 (Mifepristone)PhaseNot recordedRegistry statusCompletedTreatment of Schizoaffective Disorder Using Mifepristone
NCT00725270 · start 1998-04
Registered record
- Registry ID
- NCT00725270
- Conditions
- Psychotic Disorders; Depressive Disorder, Major; Depressive Disorder
- Interventions
- Mifepristone; Placebo Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Terminated
- Start
- 1998-04
- Completion
- 2009-05
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPsychotic Disorders; Depressive Disorder, Major; Depressive DisorderInterventionMifepristone; Placebo Oral TabletPhasePhase 2 / Phase 3Registry statusTerminatedTermination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone
NCT00206193
Registered record
- Registry ID
- NCT00206193
- Conditions
- Abortion, Induced
- Interventions
- mifepristone; misoprostol; sulprostone
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, InducedInterventionmifepristone; misoprostol; sulprostonePhaseNot recordedRegistry statusUnknown